NO20024853L - Fremgangsmate for seleksjon og testing av forbindelser som inhiberer klonal cellevekst og anvendelse av slike forbindelser - Google Patents

Fremgangsmate for seleksjon og testing av forbindelser som inhiberer klonal cellevekst og anvendelse av slike forbindelser

Info

Publication number
NO20024853L
NO20024853L NO20024853A NO20024853A NO20024853L NO 20024853 L NO20024853 L NO 20024853L NO 20024853 A NO20024853 A NO 20024853A NO 20024853 A NO20024853 A NO 20024853A NO 20024853 L NO20024853 L NO 20024853L
Authority
NO
Norway
Prior art keywords
compounds
selecting
methods
cell growth
clonal cell
Prior art date
Application number
NO20024853A
Other languages
English (en)
Other versions
NO20024853D0 (no
NO326130B1 (no
Inventor
Enok Tjotta
Original Assignee
Enok Tjotta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enok Tjotta filed Critical Enok Tjotta
Priority to NO20024853A priority Critical patent/NO326130B1/no
Publication of NO20024853D0 publication Critical patent/NO20024853D0/no
Priority to PCT/NO2003/000335 priority patent/WO2004055175A1/en
Priority to CA002501039A priority patent/CA2501039A1/en
Priority to EP03811277.7A priority patent/EP1549742B1/en
Priority to AU2003302154A priority patent/AU2003302154B2/en
Priority to US10/530,488 priority patent/US20060121449A1/en
Publication of NO20024853L publication Critical patent/NO20024853L/no
Priority to ZA200502609A priority patent/ZA200502609B/en
Publication of NO326130B1 publication Critical patent/NO326130B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20024853A 2002-10-08 2002-10-08 Fremgangsmate for seleksjon og testing av forbindelser som inhiberer eller stimulerer klonal cellevekst NO326130B1 (no)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NO20024853A NO326130B1 (no) 2002-10-08 2002-10-08 Fremgangsmate for seleksjon og testing av forbindelser som inhiberer eller stimulerer klonal cellevekst
PCT/NO2003/000335 WO2004055175A1 (en) 2002-10-08 2003-10-07 Method for selection of compounds which inhibit clonal cell growth and use thereof
CA002501039A CA2501039A1 (en) 2002-10-08 2003-10-07 Method for selection of compounds which inhibit clonal cell growth and use thereof
EP03811277.7A EP1549742B1 (en) 2002-10-08 2003-10-07 Method for selection of compounds which inhibit clonal cell growth and use thereof
AU2003302154A AU2003302154B2 (en) 2002-10-08 2003-10-07 Method for selection of compounds which inhibit clonal cell growth and use thereof
US10/530,488 US20060121449A1 (en) 2002-10-08 2003-10-07 Method for selection of compounds which inhibit clonal cell growth and use thereof
ZA200502609A ZA200502609B (en) 2002-10-08 2005-03-31 Method for selection of compounds which inhibit clonal call growth and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO20024853A NO326130B1 (no) 2002-10-08 2002-10-08 Fremgangsmate for seleksjon og testing av forbindelser som inhiberer eller stimulerer klonal cellevekst

Publications (3)

Publication Number Publication Date
NO20024853D0 NO20024853D0 (no) 2002-10-08
NO20024853L true NO20024853L (no) 2004-04-13
NO326130B1 NO326130B1 (no) 2008-10-06

Family

ID=19914079

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024853A NO326130B1 (no) 2002-10-08 2002-10-08 Fremgangsmate for seleksjon og testing av forbindelser som inhiberer eller stimulerer klonal cellevekst

Country Status (7)

Country Link
US (1) US20060121449A1 (no)
EP (1) EP1549742B1 (no)
AU (1) AU2003302154B2 (no)
CA (1) CA2501039A1 (no)
NO (1) NO326130B1 (no)
WO (1) WO2004055175A1 (no)
ZA (1) ZA200502609B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317268D0 (en) 2003-07-23 2003-08-27 Viral Asa A Compounds
EP2368558A1 (en) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates
US10976320B2 (en) * 2013-05-21 2021-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods for identifying and treating cancer patients

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744985A (en) * 1979-08-24 1988-05-17 Toyama Chemical Co., Ltd. Novel substances having carcinostatic and immunostimulating activity, process for preparing the same and carcinostatic agent containing the same
JPH0610141B2 (ja) * 1986-02-14 1994-02-09 新技術事業団 エイズウイルス性疾患処置剤
US5597798A (en) * 1990-03-05 1997-01-28 The Regents Of The University Of California Taxol and epidermal growth factor used to enhance treatment of ovarian cancer
US5639600A (en) * 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
JP3190011B2 (ja) * 1997-05-23 2001-07-16 ローム株式会社 強誘電体記憶素子およびその製造方法
JP2002509884A (ja) * 1998-03-28 2002-04-02 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 癌の化学防御におけるｄｆｍｏ及びスリンダクの組合せ
US6201028B1 (en) * 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
GB9915184D0 (en) * 1999-06-29 1999-09-01 Viral As A Compounds
EP2481814A3 (en) * 2003-06-09 2012-10-10 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
US20060121449A1 (en) 2006-06-08
AU2003302154B2 (en) 2008-06-12
NO20024853D0 (no) 2002-10-08
WO2004055175A1 (en) 2004-07-01
CA2501039A1 (en) 2004-07-01
NO326130B1 (no) 2008-10-06
AU2003302154A1 (en) 2004-07-09
EP1549742B1 (en) 2014-01-08
ZA200502609B (en) 2006-07-26
EP1549742A1 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
DK1499311T3 (da) Substituerede benzaboler og anvendelse deraf som RAF-kinaseinhibitorer
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
NO20044095L (no) 5-fenyltiazolderivater og anvendelse som P13 kinaseinhibitorer
DK1713806T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK1606283T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS2675B (is) P38-hindrar og aðferðir til notkunar þeirra
DK1437106T3 (da) Prøveimplantatsæt
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
DK1730146T3 (da) Azaindoler anvendelige som inhibitorer af JAK og andre proteinkinaser
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
DK2305250T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
IS2565B (is) Aðferðir og lyfjasamsetningar til að ná áreiðanlega ásættanlegum testósterónstyrk í sermi
NO20052888D0 (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
DK1756064T3 (da) Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
NO20061906L (no) Terapeutisk middel for mesoteliom
DK1527050T3 (da) Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
IS7505A (is) Pýrróló-tríazín anilín efnasambönd gagnleg sem kínasatálmar
DK1830926T3 (da) Oreganomundplejesammensætninger og fremgangsmåde til anvendelse heraf
NO20050620L (no) Nye 2-aryltiazol-forbindelser som PPARALPHA og PPARGAMA agonister
NO20053874D0 (no) Formulering og metoder for behandling av thrombocytemi
DK2617714T3 (da) Kemiske derivater af jasmonat, farmaceutiske præparater og fremgangsmåder til anvendelse deraf
NO20040996L (no) Nye forbindelser og sammensetninger som catepsin-inhibitorer
DK1655030T3 (da) Benzothiadiazinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger, som indeholder disse
DK1511764T3 (da) Peptider og peptidomimetika, som er egnede til hæmning af aktiviteten af prostaglandin f2alfa-receptor

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees